Get the Stockscreener App
9.55
4.40%
-0.44
After Hours:
9.52
-0.03
-0.31%
Avalo Therapeutics Inc stock is traded at $9.55, with a volume of 36,063.
It is down -4.40% in the last 24 hours and down -33.86% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$9.99
Open:
$9.99
24h Volume:
36,063
Relative Volume:
0.92
Market Cap:
$102.54M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-4.4626
EPS:
-2.14
Net Cash Flow:
$-36.78M
1W Performance:
-12.39%
1M Performance:
-33.86%
6M Performance:
-27.10%
1Y Performance:
+10,360%
1-Day Range:
$9.31
$9.99
1-Week Range:
$9.14
$10.88
52-Week Range:
$0.0333
$34.46
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
540 GAITHER ROAD, ROCKVILLE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
9.55 | 102.54M | 1.93M | -7.96M | -36.78M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics (FRA:C6K0) Cash From Other Investing Act - GuruFocus.com
Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio : 0.02 (As of Nov. 21, 2024) - GuruFocus.com
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday - MSN
(AVTX) Investment Analysis and Advice - Stock Traders Daily
Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc - GuruFocus.com
Avalo Therapeutics director June Almenoff acquires $12,749 in stock - Investing.com
Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants - MSN
Avalo Therapeutics secures $69.4 million from warrant exercise By Investing.com - Investing.com Australia
Avalo Therapeutics Closes $69.4 Million Financing - citybiz
Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants - TipRanks
Avalo Therapeutics secures $69.4 million from warrant exercise - Investing.com India
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewswire Inc.
Avalo Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year - TipRanks
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Where are the Opportunities in (AVTX) - Stock Traders Daily
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World
When (AVTX) Moves Investors should Listen - Stock Traders Daily
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com
Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial - GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Yahoo Finance
Ikarian Capital, LLC Adjusts Stake in Avalo Therapeutics Inc - GuruFocus.com
(AVTX) Technical Pivots with Risk Controls - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World
Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective
Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
How To Trade (AVTX) - Stock Traders Daily
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World
Avalo Therapeutics regains Nasdaq compliance - Investing.com
Avalo Announces Participation in September Investor Conferences - GlobeNewswire
Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World
Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World
Avalo Therapeutics Shareholders Back Board and Strategies - TipRanks
Avalo Therapeutics sees cash runway into 2027 - TipRanks
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - citybiz
Avalo Therapeutics Inc expected to post a loss of $6.70 a shareEarnings Preview - XM
Natixis Lowers Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
(AVTX) Long Term Investment Analysis - Stock Traders Daily
The 3 Best Personalized Nutrition Stocks to Buy Now - InvestorPlace
Avalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% - Defense World
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):